Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets September 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference September 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results August 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets August 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit July 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results May 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 May 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event March 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing March 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences March 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 February 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform December 22, 2022 at 11:15 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 November 14, 2022 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2022 Operating and Financial Results November 09, 2022 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference November 03, 2022 at 11:00 AM UTC
Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs August 11, 2022 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2022 Operating and Financial Results August 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium June 28, 2022 at 11:00 AM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates June 01, 2022 at 11:00 AM UTC